We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+41.14%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.71B
AUM Growth
-$3.29B
Cap. Flow
-$4.28B
Cap. Flow %
-91.04%
Top 10 Hldgs %
76.49%
Holding
126
New
17
Increased
33
Reduced
15
Closed
22

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$44.9M
2
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$20.1M
3
BPMC
Blueprint Medicines
BPMC
+$19.9M
4
NKTR icon
Nektar Therapeutics
NKTR
+$15.4M
5
AUTL
Autolus Therapeutics
AUTL
+$13.9M

Top Sells

Rank Stock Value
1
BUFF
Blue Buffalo Pet Products, Inc
BUFF
+$3.48B
2
WW
WW International
WW
+$678M
3
INCY icon
Incyte
INCY
+$25M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.8M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$13.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 44.73%
2 Healthcare 36.09%
3 Communication Services 0%
4 Consumer Staples 0%
5 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IOVA icon
51
Iovance Biotherapeutics
IOVA
$2.04B
$8.96M 0.19%
700,000
+240,000
+52% +$3.51M
SLDB icon
52
Solid Biosciences
SLDB
$788M
$8.91M 0.19%
16,667
+6,667
+67% +$2.05M
RCKT icon
53
Rocket Pharmaceuticals
RCKT
$335M
$7.85M 0.17%
400,000
+150,000
+60% +$2.84M
BLUE
54
CALL
DELISTED
bluebird bio
BLUE
$7.85M 0.17%
+3,860
New +$8.8M
FOLD
55
CALL
DELISTED
Amicus Therapeutics
FOLD
$7.81M 0.17%
500,000
-400,000
-44% -$6.05M
DNLI icon
56
Denali Therapeutics
DNLI
$3.79B
$7.63M 0.16%
500,000
+50,000
+11% +$942K
LJPC
57
DELISTED
La Jolla Pharmaceutical Company
LJPC
$7.29M 0.16%
250,000
-50,000
-17% -$1.54M
IMUX icon
58
Immunic
IMUX
$178M
$6.85M 0.15%
2,500
– –
RNAC icon
59
Cartesian Therapeutics
RNAC
$224M
$6.63M 0.14%
16,667
+12,500
+300% +$4.43M
WHWK
60
Whitehawk Therapeutics
WHWK
$176M
$6.47M 0.14%
+103,893
New +$6.28M
STML
61
DELISTED
Stemline Therapeutics, Inc.
STML
$6.42M 0.14%
400,000
– –
TBIO
62
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$6.33M 0.13%
+500,000
New +$6.04M
AGEN
63
Agenus
AGEN
$279M
$6.24M 0.13%
140,113
– –
ACIU icon
64
AC Immune
ACIU
$233M
$5.59M 0.12%
600,000
– –
TGTX icon
65
TG Therapeutics
TGTX
$8.31B
$5.26M 0.11%
400,000
+150,000
+60% +$2.06M
DRNA
66
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.21M 0.11%
425,000
– –
SPRO icon
67
Spero Therapeutics
SPRO
$67.7M
$5.13M 0.11%
350,000
– –
ACET icon
68
Adicet Bio
ACET
$76.7M
$5.03M 0.11%
4,911
+893
+22% +$961K
XLRN
69
CALL
DELISTED
Acceleron Pharma
XLRN
$4.85M 0.1%
+100,000
New +$3.64M
AKBA icon
70
Akebia Therapeutics
AKBA
$335M
$4.74M 0.1%
475,000
– –
CLVS
71
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
$4.55M 0.1%
100,000
-150,000
-60% -$7.3M
AGIO icon
72
CALL
Agios Pharmaceuticals
AGIO
$2.1B
$4.21M 0.09%
50,000
– –
IRWD icon
73
Ironwood Pharmaceuticals
IRWD
$614M
$4.15M 0.09%
258,954
– –
CBIO
74
Crescent Biopharma
CBIO
$598M
$4.03M 0.09%
2,500
-750
-23% -$1.29M
SYBX
75
DELISTED
Synlogic
SYBX
$3.93M 0.08%
26,667
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2018 Portfolio in Review

As of Q2 2018, Artal Group held 126 positions worth $4.71B, down 41% from $7.99B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Artal Group withdrew a net $4.28B in Q2 2018, closing 22 positions and reducing 15 holdings. Its most notable exit was Blue Buffalo Pet Products, Inc, an estimated $3.48B position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 45% of assets, up from 23% a quarter earlier, followed by Healthcare and Communication Services.

Against the trend, Artal Group opened a new position in Scholar Rock worth $37.4M.

  • Artal Group's largest Q2 2018 buy was Scholar Rock: 2,396,040 shares worth $37.4M.
  • Artal Group added most to Lexicon Pharmaceuticals in Q2 2018, an estimated $20.1M increase.
  • Artal Group's biggest Q2 2018 reduction was WW International, cutting an estimated $678M.
  • Artal Group fully exited Blue Buffalo Pet Products, Inc in Q2 2018, selling an estimated $3.48B.
  • Artal Group's ten largest holdings make up 76% of its $4.71B portfolio in Q2 2018.
  • Artal Group opened 17 new positions and closed 22 in Q2 2018.
  • Artal Group's portfolio value fell 41% quarter-over-quarter to $4.71B.

Based on Artal Group's 13F filing for Q2 2018, filed 10 Aug 2018.